Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/49787
SCREENING OF CHEMICAL LIBRARIES FOR NEW ANTIFUNGAL DRUGS AGAINST ASPERGILLUS FUMIGATUS REVEALS SPHINGOLIPIDS ARE INVOLVED IN THE MECHANISM OF ACTION OF MILTEFOSINE
Esfingolípidos
Factores de Transcripción Activadores
Reposicionamento de Medicamentos
Esfingolipídeos
Fatores Ativadores da Transcrição
Author
Reis, Thaila Fernanda dos
Horta, Maria Augusta Crivelente
Colabardini, Ana Cristina
Fernandes, Caroline Mota
Silva, Lilian Pereira
Bastos, Rafael Wesley
Fonseca, Maria Vitória de Lazari
Wang, Fang
Martins, Celso
Rodrigues, Marcio Lourenço
Pereira, Cristina Silva
Poeta, Maurizio del
Wong, Koon Ho
Goldman, Gustavo H.
Horta, Maria Augusta Crivelente
Colabardini, Ana Cristina
Fernandes, Caroline Mota
Silva, Lilian Pereira
Bastos, Rafael Wesley
Fonseca, Maria Vitória de Lazari
Wang, Fang
Martins, Celso
Rodrigues, Marcio Lourenço
Pereira, Cristina Silva
Poeta, Maurizio del
Wong, Koon Ho
Goldman, Gustavo H.
Affilliation
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil. / MicroControl Innovation Ltd. Ribeirão Preto, São Paulo, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Department of Microbiology and Immunology. Stony Brook University. Stony Brook, New York, USA.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Faculty of Health Sciences. University of Macau. Taipa, Macau, China.
Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier. Oeiras, Portugal.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil. / Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier. Oeiras, Portugal.
Department of Microbiology and Immunology. Stony Brook University. Stony Brook, New York, USA. / Veteran Administration Medical Center. Northport, New York, USA. / iMicroRid Technologies Inc. Dix Hills, New York, USA. / Division of Infectious Diseases. School of Medicine. Stony Brook University. Stony Brook, New York, USA.
Faculty of Health Sciences. University of Macau. Taipa, Macau, China. / Institute of Translational Medicine. Faculty of Health Sciences. University of Macau. Taipa, Macau, China. / Ministry of Education. Frontiers Science Center for Precision Oncology. University of Macau. Taipa, Macau, China.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Department of Microbiology and Immunology. Stony Brook University. Stony Brook, New York, USA.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Faculty of Health Sciences. University of Macau. Taipa, Macau, China.
Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier. Oeiras, Portugal.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil. / Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier. Oeiras, Portugal.
Department of Microbiology and Immunology. Stony Brook University. Stony Brook, New York, USA. / Veteran Administration Medical Center. Northport, New York, USA. / iMicroRid Technologies Inc. Dix Hills, New York, USA. / Division of Infectious Diseases. School of Medicine. Stony Brook University. Stony Brook, New York, USA.
Faculty of Health Sciences. University of Macau. Taipa, Macau, China. / Institute of Translational Medicine. Faculty of Health Sciences. University of Macau. Taipa, Macau, China. / Ministry of Education. Frontiers Science Center for Precision Oncology. University of Macau. Taipa, Macau, China.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil.
Abstract
Aspergillus fumigatus is an important fungal pathogen and the main etiological agent of aspergillosis, a disease characterized by a noninvasive process that can evolve to a more severe clinical manifestation, called invasive pulmonary aspergillosis (IPA), in immunocompromised patients. The antifungal arsenal to threat aspergillosis is
very restricted. Azoles are the main therapeutic approach to control IPA, but the emergence of azole-resistant A. fumigatus isolates has significantly increased over recent decades. Therefore, new strategies are necessary to combat aspergillosis, and drug repurposing has emerged as an efficient and alternative approach for identifying new antifungal drugs. Here, we used a screening approach to analyze A. fumigatus in vitro
susceptibility to 1,127 compounds. A. fumigatus was susceptible to 10 compounds, including miltefosine, a drug that displayed fungicidal activity against A. fumigatus. By screening an A. fumigatus transcription factor null library, we identified a single mutant, which has the smiA (sensitive to miltefosine) gene deleted, conferring a phenotype of susceptibility to miltefosine. The transcriptional profiling (RNA-seq) of the wild-type and
DsmiA strains and chromatin immunoprecipitation coupled to next-generation sequencing (ChIP-Seq) of an SmiA-tagged strain exposed to miltefosine revealed genes of the sphingolipid pathway that are directly or indirectly regulated by SmiA. Sphingolipid analysis demonstrated that the mutant has overall decreased levels of sphingolipids when growing in the presence of miltefosine. The identification of SmiA represents the
first genetic element described and characterized that plays a direct role in miltefosine response in fungi.
Keywords in Portuguese
MiltefosinaKeywords in Spanish
Reposicionamiento de MedicamentosEsfingolípidos
Factores de Transcripción Activadores
DeCS
Aspergillus fumigatusReposicionamento de Medicamentos
Esfingolipídeos
Fatores Ativadores da Transcrição
Share